Reduced LRRK2-positive neurons in the striatum of Parkinson’s disease patients hypothesize a retrograde disease mechanism?
Basal Ganglia, ISSN: 2210-5336, Vol: 2, Issue: 2, Page: 67-72
2012
- 2Citations
- 10Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
One major unsolved question in leucine-rich repeat kinase 2 (LRRK2)-mediated dopaminergic degeneration in Parkinson disease (PD) is the discrepancy between the preferentially diseased neuron type (dopamine neurons within substantia nigra ) and the expression pattern of LRRK2 (highest expression within dopamine neuron target areas, striatum). We investigated LRRK2 mRNA and protein expression pattern in the Substantia nigra pars compacta as well as the striatum ( caudate nucleus ) in human brain specimens of sporadic PD patients ( n = 10) and age-matched controls ( n = 14). We did not find any differences in healthy and diseased Substantia nigra pars compacta with no detectable LRRK2 protein expression in dopamine neurons in both conditions. Contrary, we observed a significant reduction of LRRK2-immunoreactive neurons in the striatum in PD compared to controls. Our data question a cell-intrinsic pathophysiological role of LRRK2 in Substantia nigra pars compacta dopamine neurons, but might indicate a role of LRRK2 in retrograde deterioration of dopamine neurons coming out of their projection area.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2210533612000524; http://dx.doi.org/10.1016/j.baga.2012.04.030; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84862862832&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S2210533612000524; https://dx.doi.org/10.1016/j.baga.2012.04.030
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know